Fox Christine 4

What Happened

• Christine Fox, EVP, U.S. Commercial of Teva Pharmaceutical Industries (TEVA), had restricted share units vest and completed related derivative transactions on March 4, 2026. She sold 9,098 shares in an open‑market transaction at a weighted average price of $32.46 for proceeds of $295,362. The filing also reports conversion/exercise entries for 20,461 derivative shares and a new grant of 50,643 restricted share units (RSUs) on the same date.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (appears timely).
• Open‑market sale: 9,098 shares, weighted average price $32.46, total reported proceeds $295,362. Price range for the sale: $32.095–$33.30 (multiple transactions, per filing).
• Derivative activity: two exercise/conversion (code M) entries for 20,461 shares and one derivative disposal reported at $0 (per filing).
• Grant: 50,643 RSUs awarded on March 4, 2026 (see vesting schedule in footnote).
• Footnotes: sale executed under a Rule 10b5‑1 plan adopted Aug 11, 2025 (F3); the sale of shares was to cover tax withholding on vesting RSUs (F4); RSU vesting schedules provided (F6, F7).
• Shares owned after the transactions: not specified in the excerpted details of the filing.

Context

• This activity looks like routine compensation settlement: RSUs vested, some shares were converted/settled, and a portion was sold (through a 10b5‑1 plan) to cover tax obligations. Such tax‑withholding sales are common and do not by themselves indicate a change in insider sentiment. Purchases are generally a stronger signal of insider bullishness; this filing primarily reports a sale and a new RSU grant (award).